Lipsky, A. H., & Lamanna, N. (2024). SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.11.016

Geskin, L. J., Angello, J. T., Bagot, M., Guenova, E., Nikbakht, N., Querfeld, C., & Scarisbrick, J. J. (2024). Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facilitate Optimal Treatment Experiences. Clinical Lymphoma Myeloma and Leukemia, 24(1), 40–47. https://doi.org/10.1016/j.clml.2023.08.020

Cherng, H.-J., Capaccione, K., Ma, H., Jambawalikar, S., Orlando, E., Ford, M., Gould, P., Cuzzo, B., Lipsky, A., Pro, B., & Amengual, J. (2023). ABCL-600 Diagnostic Utility of the 18F-FDG PET/CT Scan in EBV-Positive Solid Organ Transplant Patients at Risk for Post-Transplant Lymphoproliferative Disorder. Clinical Lymphoma Myeloma and Leukemia, 23, S442. https://doi.org/10.1016/s2152-2650(23)01337-x

Nastoupil, L. J., Andersen, C., Ayers, A., Wang, Y., Habermann, T. M., Chihara, D., Kahl, B. S., Link, B. K., Ayyappan, S., Cohen, J. B., Martin, P., Lossos, I. S., Casulo, C., Lin, R., Li, Z., Larson, M. A., Maurer, M. J., Huynh, L., Gao, C., … Flowers, C. R. (2023). ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy. Clinical Lymphoma Myeloma and Leukemia, 23, S442–S443. https://doi.org/10.1016/s2152-2650(23)01338-1

Klausz, K., Gehlert, C. L., Krohn, S., Winterberg, D., Lustig, M., Boje, A. S., Besse, L., Besse, A., Driessen, C., Peipp, M., & Gramatzki, M. (2023). P-198 Impact of blocking the CD47 axis on phagocytosis of myeloma cells treated with CD38 antibodies and proteasome inhibitors. Clinical Lymphoma Myeloma and Leukemia, 23, S144–S145. https://doi.org/10.1016/s2152-2650(23)01816-5

Li, S., Fu, J., Liu, G., Ma, H., Mapara, M., Marcireau, C., & Lentzsch, S. (2023). P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism. Clinical Lymphoma Myeloma and Leukemia, 23, S145–S146. https://doi.org/10.1016/s2152-2650(23)01818-9

Baljevic, M., Moreau, P., Tuchman, S., Callander, N., Lentzsch, S., Van Domelen, D., Bentur, O., Monge, J., & Biran, N. (2023). P-232 Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. Clinical Lymphoma Myeloma and Leukemia, 23, S163. https://doi.org/10.1016/s2152-2650(23)01850-5

Dhodapkar, M., Bumma, N., Richter, J., Lee, H., Hoffman, J., Suvannasankha, A., Lentzsch, S., Shah, M., Zonder, J., Baz, R., Wu, K. L., Pianko, M., Silbermann, R., Min, C.-K., Vekemans, M.-C. M., Munder, M., Byun, J. M., Lopez, J. M., DeVeaux, M., … Jagannath, S. (2023). P-247 Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study. Clinical Lymphoma Myeloma and Leukemia, 23, S172. https://doi.org/10.1016/s2152-2650(23)01865-7

Fu, J., Li, S., Ma, H., Liu, G., Mapara, M., & Lentzsch, S. (2023). P-391 Checkpoint inhibitor PD-1H/VISTA mediates its effects on osteoclast cytoskeleton in myeloma bone disease via c-Src/Rac1 signaling. Clinical Lymphoma Myeloma and Leukemia, 23, S256. https://doi.org/10.1016/s2152-2650(23)02009-8

Karimi, Y., Ghesquieres, H., Jurczak, W., Cheah, C. Y., Clausen, M. R., Lugtenburg, P., Cunningham, D., Do, Y. R., Lewis, D. J., Gasiorowski, R., Kim, T. M., van der Poel, M., Poon, M. L., Feldman, T., Linton, K. M., Sureda, A., Hutchings, M., Stirner, M. C., Liu, Y., … Thieblemont, C. (2023). POSTER: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial. Clinical Lymphoma Myeloma and Leukemia, 23, S203. https://doi.org/10.1016/s2152-2650(23)00718-8

Masaquel, A., Li, J., Ho, R., Fox, D., Rosettie, K. L., El Moustaid, F., Qu, T., & Meng, Y. (2023). POSTER: ABCL-504 Population Health and Economic Benefits of Pola-R-CHP versus R-CHOP in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in the United States. Clinical Lymphoma Myeloma and Leukemia, 23, S203. https://doi.org/10.1016/s2152-2650(23)00719-x

Cherng, H.-J., Capaccione, K., Ma, H., Jambawalikar, S., Orlando, E., Ford, M., Gould, P., Cuzzo, B., Lipsky, A., Pro, B., & Amengual, J. (2023). POSTER: ABCL-600 Diagnostic Utility of the 18F-FDG PET/CT Scan in EBV-Positive Solid Organ Transplant Patients at Risk for Post-Transplant Lymphoproliferative Disorder. Clinical Lymphoma Myeloma and Leukemia, 23, S203. https://doi.org/10.1016/s2152-2650(23)00722-x

VanderVeer, E., Huang, S. J. T., Bruyere, H., Li, C., Ramadan, K., Villa, D., Scott, D. W., Savage, K. J., Connors, J. M., Sehn, L. H., Toze, C. L., & Gerrie, A. S. (2023). POSTER: CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys. Clinical Lymphoma Myeloma and Leukemia, 23, S173. https://doi.org/10.1016/s2152-2650(23)00531-1

Hijiya, N., Heneghan, M., Kapoor, S., Dhamal, V., Hoch, M., Descamps, L., Cardoso, A. P., & Pollard, J. (2023). POSTER: CML-532 ASC4KIDS: A Multicenter, Open-Label, Phase 1b/2 Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00574-8

Muehlenbein, C. E., Coombs, C. C., Shah, N. N., Jurczak, W., Woyach, J., Cheah, C. Y., Patel, K., Maddocks, K., Wang, Y., Wang, C., Abhyankar, S., Tsai, D. E., & Eyre, T. A. (2023). POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00883-2

Konig, H., Tam, C. S., Lamanna, N., Jurczak, W., Kontos, A., Ruppert, A. S., & Tsai, D. E. (2023). POSTER: CT-168 Comparison of Bleeding-Related Events in Patients Who Received Pirtobrutinib With and Without Antithrombotic Agents. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00884-4

Schlenk, R. F., Montesinos, P., Romero-Aguilar, A., Vrhovac, R., Patkowska, E., Kim, H.-J., Zak, P., Wang, P.-N., Hanyok, J., Liu, L., Kamel, Y. M., Lesegretain, A., Cortes, J., Sekeres, M. A., Dombret, H., Amadori, S., Wang, J., Perl, A. E., Levis, M. J., & Erba, H. P. (2023). POSTER: CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00885-6

Coughlan, A., Klijn, S. L., Xiao, H., White, B., Litkiewicz, M., Kadambi, A., Sichevaya, A., Hnoosh, A., Miteva, D., & Yucel, A. (2023). POSTER: MDS-008 Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS). Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00575-x

Niehus, H., Sabile, J., Maziarz, R. T., Meyers, G., Cook, R., Gandhi, A., Saultz, J. N., Rakshe, S., Kaempf, A., Braun, T., & Migdady, Y. (2023). POSTER: MDS-009 Enhanced Survival of Chronic Myelomonocytic Leukemia (CMML)-Dysplastic Over the Proliferative Subtype After Allogeneic Hematopoietic Cell Transplantation: A Tertiary Center Experience. Clinical Lymphoma Myeloma and Leukemia, 23, S180. https://doi.org/10.1016/s2152-2650(23)00576-1

Shadman, M., Manzoor, B. S., Sail, K., Tuncer, H. H., Allan, J. N., Ujjani, C., Emechebe, N., Kamalakar, R., Coombs, C. C., Leslie, L., Barr, P. M., Brown, J. R., Eyre, T. A., Rampotas, A., Schuh, A., Lamanna, N., Skarbnik, A., Roeker, L. E., Bannerji, R., … Mato, A. R. (2023). Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clinical Lymphoma Myeloma and Leukemia, 23(7), 515–526. https://doi.org/10.1016/j.clml.2023.03.010

Ford, M., Jin, Z., Orlando, E., Lipsky, A., Sawas, A., Pro, B., & Amengual, J. (2022). ABCL-542 Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder. Clinical Lymphoma Myeloma and Leukemia, 22, S382–S383. https://doi.org/10.1016/s2152-2650(22)01546-4

Pratz, K. W., Cherry, M., Podoltsev, N. A., Altman, J. K., Perl, A. E., Cooper, B. W., Jurcic, J. G., Lin, T. L., Schiller, G. J., Wu, R., Hill, J. E., Gill, S. C., James, A., Rich, E. S., Hasabou, N., & Levis, M. J. (2022). AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results. Clinical Lymphoma Myeloma and Leukemia, 22, S230. https://doi.org/10.1016/s2152-2650(22)01255-1

Pemmaraju, N., Cuglievan, B., Lasky, J., Kheradpour, A., Hijiya, N., Stein, A. S., Meshinchi, S., Mullen, C., Angelucci, E., Vinti, L., Mughal, T. I., & Pawlowska, A. (2022). AML-392 Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123-Targeted Therapy. Clinical Lymphoma Myeloma and Leukemia, 22, S244–S245. https://doi.org/10.1016/s2152-2650(22)01284-8

Pammaraju, N., Kantarjian, H., Sweet, K., Wang, E. S., Lane, A. A., Ali, H., Stein, A. S., Yacoub, A., Rizzieri, D., Vasu, S., Gupta, V., Lee, S., Schiller, G. J., Foran, J. M., Taparia, M. S., Rosenblat, T. L., Walter, R. B., Sieminski, D., Anant, M., … Konopleva, M. (2022). AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies. Clinical Lymphoma Myeloma and Leukemia, 22, S246–S247. https://doi.org/10.1016/s2152-2650(22)01287-3

Sallman, D., Malki, M. A., Asch, A., Wang, E., Jurcic, J., Bradley, T., Flinn, I., Pollyea, D., Kambhampati, S., Tanaka, T., Zeidner, J., Garcia-Manero, G., Jeyakumar, D., Gu, L., Tan, A., Chao, M., O’Hear, C., Lal, I., Vyas, P., & Daver, N. (2022). MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results. Clinical Lymphoma Myeloma and Leukemia, 22, S314–S315. https://doi.org/10.1016/s2152-2650(22)01415-x

Zonder, J. A., Richter, J., Bumma, N., Brayer, J., Hoffman, J. E., Bensinger, W. I., Wu, K. L., Xu, L., Chokshi, D., Boyapati, A., Cronier, D., Houvras, Y., Lorenc, K. R., Kroog, G. S., Dhodapkar, M. V., Lentzsch, S., Cooper, D., & Jagannath, S. (2022). MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 22, S406–S407. https://doi.org/10.1016/s2152-2650(22)01591-9

Nooka, A., Costa, L., Gasparetto, C., Richardson, P., Siegel, D., Chari, A., Lentzsch, S., Jagannath, S., & Mikhael, J. (2022). Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable. Clinical Lymphoma Myeloma and Leukemia, 22(7), e526–e531. https://doi.org/10.1016/j.clml.2022.01.014

Efficace, F., Cottone, F., Sparano, F., Caocci, G., Vignetti, M., & Chakraborty, R. (2022). Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. Clinical Lymphoma Myeloma and Leukemia, 22(7), 442–459. https://doi.org/10.1016/j.clml.2022.01.009